



2016

The Anti-Inflammatory CASPASE-12 Gene Does Not Influence SLE Phenotype in African-Americans

Trista Fuchs

Touro University California, trista.fuchs@tu.edu

Jennifer A. Kelly

Emily Simon

Touro University California

Kathy L. Sivils

Evan Hermel

Touro University California, evan.hermel@tu.edu

Follow this and additional works at: https://touroscholar.touro.edu/tucocom_pubs



Part of the [Genetic Phenomena Commons](#), and the [Immune System Diseases Commons](#)

Recommended Citation

Fuchs, T., Kelly, J. A., Simon, E., Sivils K. L., & Hermel, E. (2016). The anti-inflammatory CASPASE-12 gene does not influence SLE phenotype in African-Americans. *Immunology Letters*, 173, 21-25.

The anti-inflammatory *CASPASE-12* gene does not influence SLE phenotype in African-Americans

Trista Fuchs^a, Jennifer A Kelly^b, Emily Simon^{c,d}, Kathy L. Sivils^b and Evan Hermel^{c,d*}

^a*Public Health Program, College of Education and Health Sciences, Touro University-CA*

^b*Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK*

^c*Program in Medical Health Sciences, College of Osteopathic Medicine, Touro University-CA*

^d*Department of Basic Sciences, College of Osteopathic Medicine, Touro University-CA*

*Corresponding author

Evan Hermel

Phone: 707-638-5241

FAX: 707-638-5255

E-mail: evan.hermel@tu.edu

Running title: *CASP12 and lupus*

Keywords: CASPASE-12; INFLAMMATION; INTERLEUKIN-1, LUPUS, GENETICS, AUTOIMMUNITY

ABSTRACT

In the vast majority of human populations, the gene encoding *CASPASE-12* (*CASP12*) has a premature termination codon that precludes the production of protein. However, approximately 20% of persons of recent African descent have a single nucleotide polymorphism (#rs497116; A->G) that turns the stop codon into one encoding Arg. The subsequent functional allele is a risk factor for sepsis as it uniquely downregulates inflammatory cytokines in African-Americans (AA). To determine if *CASP12* could be protective for systemic lupus erythematosus (SLE) in AA, we genotyped AA SLE patients and controls. There was a weak association between *CASP12* genotype with the absence of anti-dsDNA autoantibodies in SLE patients. No effect was seen upon serum interleukin-1 beta levels, nor was any other protective effect noted for the *CASP12* genotype, whether upon association with SLE, or any of the 11 American College of Rheumatology classification criteria. *CASP12* genotype thus does not influence the phenotype of SLE in AA.

1. Introduction

In mice, *CASPASE-12* (*CASP12*) modulates both the inflammatory process and the cellular apoptotic pathway. A truncated pseudogene (*CASP12p1*) resulting from a premature termination mutation is found in all Caucasians and East Asians examined, and in 80% of people of African lineage [1]. Thus, while most humans lack a functional *CASP12* gene, approximately 20% of persons of African descent have a functional pseudogene that is rescued by a single nucleotide polymorphism (#rs497116; A->G) that turns the premature stop codon into one encoding Arg [2,3]. The functional allele is a risk factor for sepsis in persons of African descent due to its genotype-dependent ability block inflammasome and *CASP1* activation [4,5] which in turn down-regulates inflammatory cytokines such as interleukin-1 β (IL1 β) in responses

to pro-inflammatory mediators such as bacterial lipopolysaccharide [1]. In addition, knockout mice lacking *CASP12* are less susceptible to sepsis and death than wild-type mice [5].

A corollary to the observation that *CASP12* is a risk factor for sepsis would be that *CASP12* is protective against some inflammatory autoimmune diseases, particularly systemic lupus erythematosus (SLE), in AA populations. SLE is a serious inflammatory disease with protean manifestations that can affect any organ system. The diverse nature of SLE requires classification by the presence of no less than 4 of 11 criteria, as defined by the American College of Rheumatology [6,7]. Gender, environment, and genetic factors influence the development of SLE [8,9], with over 40 genes known to play a role in SLE pathogenesis [10]. A number of these genes are specific SLE risk factors in AA individuals [9].

AA have the highest prevalence of SLE among all ethnic groups, regardless of age, gender, or socio-economic class. They manifest the disease with greater severity and burden, and have worse prognoses and higher mortality rates [8,11,12]. AA patients tend to have more frequent organ system involvement, higher auto-antibody titers, and a more pronounced pathological course. Clinically, these patients develop organ-specific damage at a faster rate than white SLE patients [13], and are more likely to have severe disease flares [14]. We thus chose to assess the role of *CASP12* in SLE using AAs selected from the Lupus Family Registry and Repository cohort [15].

2. Material and methods

2.1 Study population

The Lupus Family Registry and Repository (LFRR) is a large, multi-ethnic cohort of SLE-affected individuals, their unaffected family members, and healthy population-based controls supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases [15]. Our study group included 714 AA SLE patients and 325 healthy, population-based AA controls (demographics provided in Table 1). Study subjects were self-defined African Americans who

satisfied at least 4 of the 11 criteria for the classification of SLE [6,7]. Sera were stored at -80° C until use.

2.2 DNA genotyping

CASP12 genotyping was performed in a single tube assay [16] by allele-specific polymerase chain reaction (PCR) using primers containing a mismatch introduced at the second base from the 3' end to improve allele specificity [17] . Primers were C12-P1 (GAGTCACTATCGAGGAAGTCTCCATG), C12-P2X (TTCTGAACTTGACCTTTTGGGGATTC), C12-P3X (TATCCAAGGTTTTCAAGTAGATCTAA), and P12-P4 (CTTCACATTACATTTTCTGTTTCTTCCATC). PCR parameters were an initial 60 sec of denaturation at 94° C, 5 sec of priming at 55° C, and 5 sec of extension at 72° C, for 30 cycles, using SpeedSTAR HS or Sapphire DNA polymerase (Takara, Madison, WI). PCR products were analyzed on a 1% agarose gel. To verify results, the polymorphic portion of *CASP12* was subjected to DNA sequencing using a high-fidelity DNA polymerase. Sequence analysis was sensitive enough to discriminate between homozygous and heterozygous individuals.

2.3 ELISA analysis

Serum interleukin-1 β (IL-1 β) levels were measured using a Biolegend (San Diego, CA) ELISA-MAX Deluxe ELISA kit according to the manufacturer's instructions.

2.4 Statistical Analyses

Pearson's chi square statistics or Fisher's exact p values (not adjusted for multiple testing) were generated for full model genetic analyses of *CASP12* using the PLINK software program [18]. Cytokine analyses included non-parametric 2-tailed t tests with Mann-Whitney corrections. $P < 0.05$ was considered statistically significant.

3. Results

3.1 *CASP12 has no overall effect on SLE in AAs*

To determine if *CASP12* is protective against SLE in AAs due to its anti-inflammatory functions, we genotyped the *CASP12* SNP rs497116 in a total of 714 AA patients and 325 AA controls (all unrelated). Eight SLE patients (1.1%) were homozygous *C12*, 152 (21.3%) were heterozygous *p1/C12*, and 554 (77.6%) were homozygous *p1* (Table 2). These frequencies were similar to our normal control group and to normal controls reported in other studies [1,3]. Allele frequencies were comparable: 88% for *p1* and 12% for *C12* alleles in cases; 87% for the *p1* allele and 13% for the *C12* allele in controls. There was no association with *CASP12* genotype and any of the 11 ACR classification criteria for SLE (Table 2) in case-control analyses, nor was there any effect by *CASP12* upon clinical criteria within patients in a case-only design, i.e., having or lacking *CASP12* did not affect a patient from being susceptible to, or protected from any particular clinical presentation (Table 3).

The LFRR did not calculate Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores for their patient population. We therefore, approximated the severity of their disease at time of enrollment by defining “severe” manifestations of SLE as any case having renal disease, plus neurological manifestations or serositis. Using these criteria, we did not observe any association between *CASP12* genotype and the more pathological presentations of SLE. Therefore, when evaluating SLE as a phenotype, there was no significant association observed with *CASP12*.

3.2 *CASP12 does not affect serum IL-1 β levels in AAs with SLE*

With the data suggesting that *CASP12* plays a protective role in one aspect of SLE, we sought to determine if the mechanism involved would be mediated by IL-1 β , the cytokine best known to be influenced by *CASP12* [1,5]. IL-1 β production by peripheral blood mononuclear

cells (PBMCs) is reduced in lupus patients compared to normal controls [19], while serum IL-1 β levels are elevated [20]. Our hypothesis was that IL-1 β would be substantially reduced in a genotype-dependent manner. In testing 29 subjects (15 patients and 14 controls), there was no significant difference in IL-1 β levels between patients and controls when evaluated by *CASP12* genotype (Fig.1a), nor was there any difference amongst individuals, when grouped by genotype only (Fig 1b).

3.3 *CASP12* protects against dsDNA antibodies of SLE in AAs.

The effect of the *CASP12* genotype was also assessed for six different autoantibodies in a case-only analysis (anti-dsDNA, -Sm, -Ro, -La, -snRNP, and -cardiolipin). Of the patients for whom we have autoantibody data, a weak but significant effect was only observed for anti-dsDNA, either with a genotypic ($p=0.045$) or allelic ($p=0.032$) model (Table S1).

4. Discussion

We have found that *CASP12* genotype is neither a risk factor nor protective against SLE in African-Americans. *CASP12* polymorphisms do not affect any of the 11 ACR classification criteria, but have, at best, a weak protective effect against the development of at least one autoantibody.

While our data do not demonstrate the *CASP12* genotype had a significant effect upon serum levels of IL-1 β or any symptomology of SLE, we recognize that we evaluated a small sample. Indeed, we observe that the cases homozygous for the *CASP12p1* allele have no IL-1 β in their serum while three of the four controls that we evaluated have between 100-400 pg/ml. As relatively low numbers of African-Americans carry both copies of *CASP12* (about 1-3% of the population [1, 3 and our data], for the number of cases evaluated, changes in even small numbers could affect the significance of the results, and therefore, replication studies

should be performed before a strong conclusion can be drawn about *CASP12* genotype and SLE, especially concerning the role of IL-1 β in lupus.

Close to 200 autoantibodies have been identified in SLE patients [21]. Such autoantibodies often function as biomarkers for disease activity, have pathogenic roles, and/or are part of diagnostic criteria [22-24]. Given the importance of their role in SLE, we tested whether *CASP12* genotype would affect the presence or absence for six different autoantibodies (anti-dsDNA, -Sm, -Ro, -La, -snRNP, and -cardiolipin). We observed, at best, a weak but significant effect for anti-dsDNA. Yet after adjusting for multiple testing in the case-control and case-case analyses, no significant results remained, and no significant effects were seen for the other autoantibodies.

In addition to *CASP12*, in humans the inflammatory caspase family includes *CASP1* (the best studied) [25], *CASP4* and *CASP5*. *CASP1* triggers inflammation and mediates inflammatory cell death by pyroptosis via the activation of IL-1 β and IL18 from inactive pro-hormones receptors [26]. Activation of *CASP1* requires assembly and activation the inflammasome complex following danger signals transmitted from pattern recognition [27]. *CASP4* and 5 are also part of the inflammasome and activated by this complex [28].

What evidence is there for overt roles for the inflammatory caspases in the pathogenesis of autoimmunity? Other than *CASP1* contributing to murine lupus [29], very little is known about the role of *CASP4* and 5 in the pathogenesis of autoimmunity [27] although data is emerging that the latter caspases are involved in autoimmune skin [30] and bowel diseases [31], along with SLE [32].

Given the reported downregulatory effects the protein exerts upon IL1 β production via inhibition of *CASP1* [1,5] it was surprising that that we observed so few effects. We expected to see reduced serum IL-1 β levels in our patient group, with the lowest levels in the *CASP12* homozygous patients, especially given that defects in the ability of PBMCs to produce IL-1 β

occur in SLE patients [19] and decreased IL-1 β levels in patient serum have been described [20]. This was not the case. It should be considered, however, that nearly all studies on IL-1 β production in SLE patients involve groups such as Caucasians or Asians who carry the *p1/p1* genotype [33]. Therefore, *CASP12*'s effects may be qualitative at the cellular level rather than quantitative at the serologic level, and other inflammatory cytokines need to be examined.

If *CASP12* is indeed downregulatory, it may fail to reduce serum concentrations of IL-1 β or other pathogenic cytokines below disease-inducing levels, but does so at the cellular level. This notion is supported by our observation that *CASP12* genotype is not protective against the development of rheumatoid arthritis (RA) in AA, but is protective against RA radiologic abnormalities [34]. Surprisingly, obese African-American children had lower serum IL6 and C-reactive protein levels, as well as less macrophage infiltration into adipose tissues, if they were *CASP12*-positive [35].

The key question that emerges: is *CASP12* actually anti-inflammatory? Our own findings bring to mind "the dog that didn't bark". *CASP12* genotype does not influence susceptibility or adverse events in African-Americans or black South Africans with community-acquired pneumonia [36]. In addition, susceptibility to *Candida* sepsis in Africans is not affected by *CASP12* genotype, nor does it have any effect on serum cytokine concentrations in septic candidiasis patients [37] or in responses to *Yersinia pestis* [38]. *CASP12*'s effects upon TNF production, which is elevated in all lupus patients, especially AA [39], is also contradictory [38,40,41]. Further, while hepatitis C virus is a IL1 β inducer [42], *CASP12* genotype has no effect in the clearance of this pathogen [43]. Confounding the metabolic findings described above by Skeldon and co-workers, no protective effects were found in African-American adults with *CASP12* when metabolic parameters or C-reactive protein levels were assessed [35].

While these differences may be due to sample size, populations tested, underlying disease states assessed, or the assay systems used, one other observation is worth noting: In

transgenic mice carrying human *CASP12*, the gene is downregulated in a gender-specific manner, due to an endogenous estrogen response element [41]. Yet there is a profound skewing of the gender ratio in SLE: 90% of AA SLE patients are female [44] while male lupus patients have a more severe phenotype and worse outcomes [45,46]. A protective *CASP12* gene product would be expected to yield the opposite ratios.

The down-regulatory effects of *CASP12* may be subtle enough that it can increase risk for bacterial sepsis, yet not interrupt the pathogenesis of autoimmunity. It may be that in other autoimmune or autoinflammatory disorders that *CASP12* has a protective role, but thus far, using *CASP12* genotype to predict protection from, or disease outcomes in rheumatic diseases, appears to be problematic.

Acknowledgements. We are grateful to Drs. Paul Goldsmith and Alison McCormick for their careful proof-reading of this manuscript. This project was supported by an intramural grant from Touro University-California, and stipends from the Touro University California-College of Osteopathic Medicine's Master of Science Program in Medical Health Sciences. JAK and KLS were supported by the LFRR NIH contract from NIAMS (N01-AR-6-2277). Dr Alejandro Gugliucci is also thanked for his long-time support. Finally, we thank the many SLE patients and controls who have participated in the LFRR.

References

- [1] Saleh M, Vaillancourt JP, Graham RK, Huyck M, Srinivasula SM, Alnemri ES, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. *Nature* 2004;429:75-79.
- [2] Fischer H, Koenig U, Eckhart L, Tschachler E. Human caspase 12 has acquired deleterious mutations. *Biochem Biophys Res Commun* 2002;293:722-726.
- [3] Kachapati K, O'Brien TR, Bergeron J, Zhang M, Dean M. Population distribution of the functional caspase-12 allele. *Hum Mutat* 2006;27:975.
- [4] LeBlanc PM, Yeretssian G, Rutherford N, Doiron K, Nadiri A, Zhu L, et al. Caspase-12 modulates NOD signaling and regulates antimicrobial peptide production and mucosal immunity. *Cell host & microbe* 2008;3:146-157.
- [5] Saleh M, Mathison JC, Wolinski MK, Bensinger SJ, Fitzgerald P, Droin N, et al. Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. *Nature* 2006;440:1064-1068.
- [6] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40:1725.
- [7] Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-1277.
- [8] Ronnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. *Semin Immunol* 2011;23:113-121.
- [9] Tsokos GC. Systemic lupus erythematosus. *N Engl J Med* 2011;365:2110-2121.
- [10] Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. *J Autoimmun* 2013;41:25-33.
- [11] Alarcon GS, McGwin G, Jr., Bastian HM, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. *Arthritis Rheum* 2001;45:191-202.
- [12] Sestak AL, Nath SK, Kelly JA, Bruner GR, James JA, Harley JB. Patients with familial and sporadic onset SLE have similar clinical profiles but vary profoundly by race. *Lupus* 2008;17:1004-1009.
- [13] Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. *Semin Arthritis Rheum* 2010;39:257-268.
- [14] Petri M, Singh S, Tesfayone H, Malik A. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. *J Rheumatol* 2009;36:2476-2480.
- [15] Rasmussen A, Sevier S, Kelly JA, Glenn SB, Aberle T, Cooney CM, et al. The lupus family registry and repository. *Rheumatology (Oxford)* 2011;50:47-59.
- [16] Waterfall CM, Cobb BD. Single tube genotyping of sickle cell anaemia using PCR-based SNP analysis. *Nucleic Acids Res* 2001;29:E119.
- [17] Pettersson M, Bylund M, Alderborn A. Molecular haplotype determination using allele-specific PCR and pyrosequencing technology. *Genomics* 2003;82:390-396.
- [18] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;81:559-575.
- [19] Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). *J Immunol* 1983;130:2651-2655.

- [20] Becker-Merok A, Eilertsen GO, Nossent JC. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. *J Rheumatol* 2010;37:2039-2045.
- [21] Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. *Autoimmun Rev* 2015;14:75-79.
- [22] Olsen NJ, Karp DR. Autoantibodies and SLE: the threshold for disease. *Nat Rev Rheumatol* 2014;10:181-186.
- [23] Pisetsky DS. Anti-DNA antibodies - quintessential biomarkers of SLE. *Nat Rev Rheumatol* 2016;12:102-110.
- [24] Rekvig OP. Anti-dsDNA antibodies as a classification criterion and a diagnostic marker for systemic lupus erythematosus: critical remarks. *Clin Exp Immunol* 2015;179:5-10.
- [25] Sollberger G, Strittmatter GE, Kistowska M, French LE, Beer HD. Caspase-4 is required for activation of inflammasomes. *J Immunol* 2012;188:1992-2000.
- [26] Shalini S, Dorstyn L, Dawar S, Kumar S. Old, new and emerging functions of caspases. *Cell death and differentiation* 2015;22:526-539.
- [27] Yazdi AS, Guarda G, D'Ombra MC, Drexler SK. Inflammatory caspases in innate immunity and inflammation. *Journal of innate immunity* 2010;2:228-237.
- [28] Sanders MG, Parsons MJ, Howard AG, Liu J, Fassio SR, Martinez JA, et al. Single-cell imaging of inflammatory caspase dimerization reveals differential recruitment to inflammasomes. *Cell death & disease* 2015;6:e1813.
- [29] Kahlenberg JM, Yalavarthi S, Zhao W, Hodgins JB, Reed TJ, Tsuji NM, et al. An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. *Arthritis & rheumatology* 2014;66:152-162.
- [30] Salskov-Iversen ML, Johansen C, Kragballe K, Iversen L. Caspase-5 expression is upregulated in lesional psoriatic skin. *The Journal of investigative dermatology* 2011;131:670-676.
- [31] Becker C, Watson AJ, Neurath MF. Complex roles of caspases in the pathogenesis of inflammatory bowel disease. *Gastroenterology* 2013;144:283-293.
- [32] Pitidhamabhorn D, Kantachuesiri S, Totemchokchyakarn K, Kitiyanant Y, Ubol S. Partial construction of apoptotic pathway in PBMC obtained from active SLE patients and the significance of plasma TNF-alpha on this pathway. *Clin Rheumatol* 2006;25:705-714.
- [33] Becker-Merok A, Ostli-Eilersten G, Lester S, Nossent J. Circulating interferon-alpha2 levels are increased in the majority of patients with systemic lupus erythematosus and are associated with disease activity and multiple cytokine activation. *Lupus* 2013;22:155-163.
- [34] Marshall L, Obaidullah M, Fuchs T, Fineberg NS, Brinkley G, Mikuls TR, et al. CASPASE-12 and rheumatoid arthritis in African-Americans. *Immunogenetics* 2014;66:281-285.
- [35] Skeldon AM, Morizot A, Douglas T, Santoro N, Kursawe R, Kozlitina J, et al. Caspase-12, but Not Caspase-11, Inhibits Obesity and Insulin Resistance. *Journal of immunology* 2016;196:437-447.
- [36] Chen J, Wilson ES, Dahmer MK, Quasney MW, Waterer GW, Feldman C, et al. Lack of association of the caspase-12 long allele with community-acquired pneumonia in people of African descent. *PloS one* 2014;9:e89194.
- [37] Rosentul DC, Plantinga TS, Scott WK, Alexander BD, van de Geer NM, Perfect JR, et al. The impact of caspase-12 on susceptibility to candidemia. *Eur J Clin Microbiol Infect Dis* 2011.
- [38] Ferwerda B, McCall MB, de Vries MC, Hopman J, Maiga B, Dolo A, et al. Caspase-12 and the inflammatory response to *Yersinia pestis*. *PloS one* 2009;4:e6870.

- [39] Weckerle CE, Mangale D, Franek BS, Kelly JA, Kumabe M, James JA, et al. Large-scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus. *Arthritis Rheum* 2012;64:2947-2952.
- [40] Plantinga TS, Hamza OJ, Willment JA, Ferwerda B, van de Geer NM, Verweij PE, et al. Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis. *J Acquir Immune Defic Syndr* 2010;55:87-94.
- [41] Yeretssian G, Doiron K, Shao W, Leavitt BR, Hayden MR, Nicholson DW, et al. Gender differences in expression of the human caspase-12 long variant determines susceptibility to *Listeria monocytogenes* infection. *Proceedings of the National Academy of Sciences of the United States of America* 2009;106:9016-9020.
- [42] Burdette D, Haskett A, Presser L, McRae S, Iqbal J, Waris G. Hepatitis C virus activates interleukin-1beta via caspase-1-inflammasome complex. *The Journal of general virology* 2012;93:235-246.
- [43] O'Brien TR, Kachapati K, Zhang M, Bergeron J, Edlin BR, Dean M. HCV infection clearance with functional or non-functional caspase-12. *Scand J Gastroenterol* 2007;42:416-417.
- [44] Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcon GS, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. *Arthritis Rheum* 2013;65:753-763.
- [45] Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. *Clin Exp Rheumatol* 2008;26:S72-79.
- [46] Campbell R, Jr., Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. *Arthritis Rheum* 2008;59:458-464.

Figure Legends

Fig 1. *CASP12* genotype has no effect upon serum levels of IL1 β when comparing patients and controls. *p1/p1*, *CASP12p1* homozygous; *C12/p1*, *CASP12p1/CASP12* heterozygous; *C12/C12*, *CASP12* homozygous. Data represent means of two-well replicates assayed via ELISA. Open circles, patients. Closed circles, normal controls.